Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agilon Health (AGL) Interest Expenses (2020 - 2025)

Historic Interest Expenses for Agilon Health (AGL) over the last 6 years, with Q3 2025 value amounting to $1.8 million.

  • Agilon Health's Interest Expenses rose 1331.69% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 147.06%. This contributed to the annual value of $6.2 million for FY2024, which is 722.44% down from last year.
  • Latest data reveals that Agilon Health reported Interest Expenses of $1.8 million as of Q3 2025, which was up 1331.69% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Agilon Health's Interest Expenses ranged from a high of $2.9 million in Q1 2021 and a low of $840000.0 during Q4 2021
  • In the last 5 years, Agilon Health's Interest Expenses had a median value of $1.6 million in 2023 and averaged $1.5 million.
  • The largest annual percentage gain for Agilon Health's Interest Expenses in the last 5 years was 9857.14% (2022), contrasted with its biggest fall of 7038.42% (2022).
  • Quarter analysis of 5 years shows Agilon Health's Interest Expenses stood at $840000.0 in 2021, then soared by 98.57% to $1.7 million in 2022, then increased by 19.48% to $2.0 million in 2023, then dropped by 21.02% to $1.6 million in 2024, then increased by 16.77% to $1.8 million in 2025.
  • Its Interest Expenses was $1.8 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.5 million in Q1 2025.